The stock boasts the one year return of 34.3%, in contrast to 16.4% for the S&P 500. This situation necessitates a ...

Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty ...

Mixed options sentiment in Hims and Hers Health (HIMS), with shares down 82c near $32.23. Options volume roughly in line with average with 81k contracts traded and calls leading puts for a put/call ...

Maple Tree Capital, an investment management company, released its Q3 2025 investor letter. A copy of the letter can be ...

A short squeeze occurs when a stock's price rises unexpectedly, forcing short sellers (who are now losing money) to ...

From optimizing healthcare resource utilization to streamlining medical records and patient data management, the Medical Information Systems industry continues to broaden its scope at a rapid pace.

Hims & Hers wants to launch its own weight loss program with GLP-1s like Ozempic. CEO Andrew Dudum worries about three challenges to the new market.

The ad that Hims & Hers Health plans to air during the Super Bowl comes at you with rapid-fire visual overload—a giant jiggling belly, bare feet on scales, X-ray results, sugary sodas, a pie in the ...

Hims & Hers compounded GLP-1 — the same ingredient as Ozempic — will be priced at $200 a month. Investors are loving the announcement.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings. Hims & Hers' ...

In recent years, we've seen a broader dialogue around the benefits of creating affordable, accessible health care for all—and whether or not it's actually achievable. While there's still plenty of ...